GlassScriptPhysician profile
Taylor J Simon
NPI 1972386746
$4,562.79
in general payments reported to CMS, 2019-2025
24 companies · $2,774 in 2025
The $2,774 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $95.77 · 2024: $1,693 · 2025: $2,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,562.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $727.79 | 2024-2025 | Rexulti, Nuedexta |
| Lundbeck LLC | $512.49 | 2024-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $482.23 | 2023-2025 | Ingrezza |
| Abbvie INC. | $370.25 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $307.52 | 2024-2025 | Caplyta |
| Alkermes, INC. | $302.93 | 2023-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $295.72 | 2024-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $262.33 | 2024-2025 | Fanapt, Hetlioz |
| Corium, LLC | $182.17 | 2024-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $163.74 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $156.89 | 2024-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $144.72 | 2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $143.47 | 2024-2025 | Austedo Xr, Austedo Xr |
| Collegium Pharmaceutical, INC. | $124.71 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $121.76 | 2023-2025 | Auvelity, Sunosi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $45.78 | 2024-2025 | Wellbutrin, Aplenzin |
| Almatica Pharma LLC | $42.20 | 2023-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $41.06 | 2025 | Qelbree |
| Livanova USA, INC. | $37.56 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Biogen, INC. | $28.66 | 2025 | Zurzuvae |
| Novo Nordisk INC | $19.98 | 2024 | Wegovy |
| Neos Therapeutics, LP | $17.34 | 2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $15.76 | 2024 | Xelstrym |
| Luye Pharma (USA) LTD. | $15.73 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.